Logo image of NVO

NOVO-NORDISK A/S-SPONS ADR (NVO) Stock Price, Quote, News and Overview

NYSE:NVO - New York Stock Exchange, Inc. - US6701002056 - ADR - Currency: USD

58.08  -4.8 (-7.63%)

Premarket: 58.7 +0.62 (+1.07%)

NVO Quote, Performance and Key Statistics

NOVO-NORDISK A/S-SPONS ADR

NYSE:NVO (4/17/2025, 8:04:00 PM)

Premarket: 58.7 +0.62 (+1.07%)

58.08

-4.8 (-7.63%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High148.15
52 Week Low57.28
Market Cap257.82B
Shares4.44B
Float4.17B
Yearly Dividend1.51
Dividend Yield2.71%
PE16.83
Fwd PE14.05
Earnings (Next)05-07 2025-05-07/bmo
IPO05-17 1974-05-17


NVO short term performance overview.The bars show the price performance of NVO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40 -50

NVO long term performance overview.The bars show the price performance of NVO in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -10 -20 -30 -40 -50

The current stock price of NVO is 58.08 USD. In the past month the price decreased by -26.29%. In the past year, price decreased by -52.67%.

NOVO-NORDISK A/S-SPONS ADR / NVO Daily stock chart

NVO Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 64.61 796.27B
JNJ JOHNSON & JOHNSON 15.67 379.48B
NVS NOVARTIS AG-SPONSORED ADR 13.96 218.96B
AZN ASTRAZENECA PLC-SPONS ADR 16.29 209.55B
MRK MERCK & CO. INC. 10.21 196.28B
PFE PFIZER INC 7.12 125.57B
SNY SANOFI-ADR 11.41 124.61B
BMY BRISTOL-MYERS SQUIBB CO 43.18 100.17B
GSK GSK PLC-SPON ADR 8.3 72.81B
ZTS ZOETIS INC 25.11 66.32B
TAK TAKEDA PHARMACEUTIC-SP ADR 31.98 46.30B
HLN HALEON PLC-ADR 21.29 46.11B

About NVO

Company Profile

NVO logo image Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Company Info

NOVO-NORDISK A/S-SPONS ADR

Novo Alle 1

Bagsvaerd 2880 DK

CEO: Lars Fruergaard Jorgensen

Employees: 69260

Company Website: https://www.novonordisk.com/

Investor Relations: https://www.novonordisk.com/investors.html

Phone: 4544448888

NOVO-NORDISK A/S-SPONS ADR / NVO FAQ

What is the stock price of NOVO-NORDISK A/S-SPONS ADR today?

The current stock price of NVO is 58.08 USD. The price decreased by -7.63% in the last trading session.


What is the ticker symbol for NOVO-NORDISK A/S-SPONS ADR stock?

The exchange symbol of NOVO-NORDISK A/S-SPONS ADR is NVO and it is listed on the New York Stock Exchange, Inc. exchange.


On which exchange is NVO stock listed?

NVO stock is listed on the New York Stock Exchange, Inc. exchange.


What is the price forecast or stock price prediction for NOVO-NORDISK A/S-SPONS ADR stock?

32 analysts have analysed NVO and the average price target is 119.67 USD. This implies a price increase of 106.05% is expected in the next year compared to the current price of 58.08. Check the NOVO-NORDISK A/S-SPONS ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is NOVO-NORDISK A/S-SPONS ADR worth?

NOVO-NORDISK A/S-SPONS ADR (NVO) has a market capitalization of 257.82B USD. This makes NVO a Mega Cap stock.


How many employees does NOVO-NORDISK A/S-SPONS ADR have?

NOVO-NORDISK A/S-SPONS ADR (NVO) currently has 69260 employees.


What are the support and resistance levels for NOVO-NORDISK A/S-SPONS ADR (NVO) stock?

NOVO-NORDISK A/S-SPONS ADR (NVO) has a resistance level at 63.03. Check the full technical report for a detailed analysis of NVO support and resistance levels.


Is NOVO-NORDISK A/S-SPONS ADR (NVO) expected to grow?

The Revenue of NOVO-NORDISK A/S-SPONS ADR (NVO) is expected to grow by 23.4% in the next year. Check the estimates tab for more information on the NVO EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy NOVO-NORDISK A/S-SPONS ADR (NVO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does NOVO-NORDISK A/S-SPONS ADR (NVO) stock pay dividends?

NOVO-NORDISK A/S-SPONS ADR (NVO) has a dividend yield of 2.71%. The yearly dividend amount is currently 1.51. Check the full fundamental report for a detailed analysis of NVO dividend history, reliability and sustainability.


When does NOVO-NORDISK A/S-SPONS ADR (NVO) report earnings?

NOVO-NORDISK A/S-SPONS ADR (NVO) will report earnings on 2025-05-07, before the market open.


What is the Price/Earnings (PE) ratio of NOVO-NORDISK A/S-SPONS ADR (NVO)?

The PE ratio for NOVO-NORDISK A/S-SPONS ADR (NVO) is 16.83. This is based on the reported non-GAAP earnings per share of 3.45 and the current share price of 58.08 USD. Check the full fundamental report for a full analysis of the valuation metrics for NVO.


What is the Short Interest ratio of NOVO-NORDISK A/S-SPONS ADR (NVO) stock?

The outstanding short interest for NOVO-NORDISK A/S-SPONS ADR (NVO) is 0.31% of its float. Check the ownership tab for more information on the NVO short interest.


NVO Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

NVO Fundamental Analysis

ChartMill assigns a fundamental rating of 8 / 10 to NVO. Both the health and profitability get an excellent rating, making NVO a very profitable company, without any liquidiy or solvency issues.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NVO Financial Highlights

Over the last trailing twelve months NVO reported a non-GAAP Earnings per Share(EPS) of 3.45. The EPS increased by 21.57% compared to the year before.


Industry RankSector Rank
PM (TTM) 34.78%
ROA 21.68%
ROE 70.38%
Debt/Equity 0.62
Chartmill High Growth Momentum
EPS Q2Q%29.12%
Sales Q2Q%30.09%
EPS 1Y (TTM)21.57%
Revenue 1Y (TTM)25.03%

NVO Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 77% to NVO. The Buy consensus is the average rating of analysts ratings from 32 analysts.

For the next year, analysts expect an EPS growth of 19.72% and a revenue growth 23.4% for NVO


Ownership
Inst Owners37.62%
Ins OwnersN/A
Short Float %0.31%
Short Ratio1.55
Analysts
Analysts76.88
Price Target119.67 (106.04%)
EPS Next Y19.72%
Revenue Next Year23.4%